OncoQR ML OG is a biotech start-up, which develops novel therapeutic vaccines to cure cancer. OncoQRs vaccines are directed against solid tumours and can be regarded as a more potent alternative to monoclonal antibodies.
OncoQR was co-founded by Dr. Geert C. Mudde, Inventor of the S-TIR_ technology platform and is also Founder and CSO of U.K based TYG oncology and S-TARget Therapeutics. OncoQR utilizes S-TARgets S-TIR Technology Platform for the development of oncology based immunotherapies and was founded as a spin-off of S-TARget therapeutics GmbH. OncoQR ML obtained an exclusive license for the use af the S-TIR technology platform in oncology, infectious diseases and autoimmune disease; S-TARget continues developing vaccines for severe allergic diseases in collaboration with Allergopharma/Merck Seronon.